Mazdutide and other dual agonists in development further expand the options
The whole underlying theme here is this stigma and bias of not recognizing obesity as a disease like we do cancer and diabetes and everything else, says Florencia Halperin, an endocrinologist and chief medical officer at Form Health, an online medical weight loss clinic, For cancer, you would never have an employer who says, We're not covering this. Amanda Bonello, founder and CEO of the GLP-1 Collective, a nonprofit organization aiming to help patients access these medications, is not surprised at the lengths patients are going to
After being reconstituted with bacteriostatic water, they must be kept refrigerated and are typically stable for several weeks, though this can vary
Verified using analytical methods such as HPLC and mass spectrometry
On 19 December 2024, the FDA removed tirzepatide from its official drug shortage list, with semaglutide expected to follow in 2025 [3]
#Oral #pills are expected to broaden uptake beyond #clinical settings by offering #convenience, #flexibility, and appeal to those hesitant about injections